

# ATTUNE™ Knee System with ATTUNE S+™ Technology – Evidence Update

## Two-year Survivorship and Clinical Outcomes of Total Knee Arthroplasty with a New Tibial Design from a Multi-Center Registry

Spitzer, Swank, Irving, Pomeroy, Croker, Fawley  
Abstract presented at EFORT Congress, Lisbon, June 22-24th 2022



The authors present a retrospective review of data generated within a multi-center outcome registry. The standard of care follow-up varied between sites therefore standardized registry visit windows were established, which were back-to-back to include all follow-up data. Kaplan-Meier (KM) survivorship was performed with revision of the tibial component and revision of any component as endpoints. For each endpoint two survivorship analyses were performed with differing censoring assumptions. First, unrevised subjects were censored at the last clinical follow-up [clinical assumption (CA)], and second at the date of database extract [registry assumption (RA)].

- A total of 2,626 knees were implanted between September 2017 and November 2021.
- Primary diagnosis was osteoarthritis in 98.9% of cases. The mean age was 67.6 and 55% were female.
- Mean knee society total scores (SD; N) were 45.0 (17.9; 1870) pre-operatively and 90.9 (11.4; 645), 92.4 (9.6; 172), and 94.1 (5.3; 50) at 1-, 2-, and 3-years post-operative.
- The tibial component was revised in 10 cases
  - 3 – Instability
  - 2 – Loosening
  - 2 – Infection
  - 2 – Pain/stiffness
  - 1 – Implant fracture

**98.6% (97.8--99.0%) survivorship at 3 years for revision of any component\***

**99.4% (98.9--99.7%) survivorship at 3 years for tibial revision\***

## Conclusions

ATTUNE™ Knee System with ATTUNE S+™ Technology is performing at or better than the TKA class, as reported within this multi-center outcome registry and two national registries<sup>1,2</sup>. When using ATTUNE S+ Technology, tibial loosening, an industry-wide challenge, is a low-risk with KM survivorship for the tibia ranging between 98.9% and 99.7% at 3 years post-operatively.

\*Registry Assumption


**References**

1. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), Automated Industry Report System (AIRS), ID No. 5901 for DePuy Synthes, ATTUNE Total Knee, (Procedures from 1 September 1999 – 4 February 2022), Generated 8 Feb 2022, AOA, Adelaide: 1-17.
2. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. Implant Summary Report for DePuy ATTUNE CR and ATTUNE PS (S+ tibial only). NJR Database extract 18 Nov 2021, page 12. Licensed for use until 24 Nov 2022.

**AOANJRR Disclaimer:** AOANJRR is confident in the accuracy of the data included in this report, at the time it was provided. However, it was generated using an automated reporting system and has not been reviewed by the AOANJRR personnel.

**NJR Disclaimer:** The data used for this analysis was obtained from the National Joint Registry (“NJR”). The Healthcare Quality Improvement Partnership (“HQIP”), the NJR and/or its contractor, Northgate Public Services (UK) Limited (“NPS”) take no responsibility for the accuracy, currency, reliability and correctness of any data used or referred to in this report, nor for the accuracy, currency, reliability and correctness of links or references to other information sources and disclaims all warranties in relation to such data, links and references to the maximum extent permitted by legislation.

**Figure 1: Cumulative Percent Revision of Primary Total Knee Replacement by Model (All Diagnoses)**



Revision at Risk	0 Yr	1 Yr	2 Yrs	3 Yrs	4 Yrs	5 Yrs	6 Yrs	7 Yrs	8 Yrs	9 Yrs
All Knee	145,733	100,950	66,211	21,611	0	0	0	0	0	0
Other Total Knee	811,195	550,700	367,732	226,132	155,497	89,740	45,644	23,648	12,419	27,407

**Table 13: Yearly Cumulative Incidence Revision Diagnosis of Primary Total Knee Replacement by Model (All Diagnoses)**

Model	Event	N Patients	1 Yr	2 Yrs	3 Yrs	5 Yrs	10 Yrs	15 Yrs
All Knee	Infection	82	0.4 (0.3, 0.5)	0.6 (0.5, 0.6)	0.7 (0.6, 0.8)	0.9 (0.8, 1.0)	1.2 (1.1, 1.3)	1.2 (1.1, 1.2)
	Loosening	22	0.1 (0.0, 0.1)	0.2 (0.1, 0.2)	0.3 (0.2, 0.3)	0.3 (0.2, 0.3)	0.3 (0.2, 0.3)	0.3 (0.2, 0.3)
	Instability	22	0.1 (0.0, 0.1)	0.2 (0.1, 0.2)	0.2 (0.1, 0.2)	0.2 (0.1, 0.2)	0.2 (0.1, 0.2)	0.2 (0.1, 0.2)
	Patellofemoral Pain	4	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)
	Pain	14	0.0 (0.0, 0.0)	0.1 (0.0, 0.1)	0.1 (0.0, 0.1)	0.1 (0.0, 0.1)	0.1 (0.0, 0.1)	0.1 (0.0, 0.1)
	Other	41	0.2 (0.1, 0.3)	0.3 (0.2, 0.3)	0.4 (0.3, 0.5)	0.4 (0.3, 0.5)	0.4 (0.3, 0.5)	0.4 (0.3, 0.5)
Other Total Knee	Infection	135	0.4 (0.3, 0.5)	0.6 (0.5, 0.6)	0.7 (0.6, 0.8)	0.9 (0.8, 1.0)	1.2 (1.1, 1.3)	1.2 (1.1, 1.2)
	Loosening	3975	0.2 (0.2, 0.2)	0.4 (0.4, 0.4)	0.5 (0.5, 0.5)	0.6 (0.6, 0.6)	0.7 (0.7, 0.7)	0.7 (0.7, 0.7)
	Instability	2488	0.1 (0.1, 0.1)	0.2 (0.2, 0.2)	0.2 (0.2, 0.2)	0.3 (0.3, 0.3)	0.4 (0.4, 0.4)	0.5 (0.5, 0.5)
	Patellofemoral Pain	2790	0.1 (0.1, 0.1)	0.2 (0.2, 0.2)	0.2 (0.2, 0.2)	0.3 (0.3, 0.3)	0.4 (0.4, 0.4)	0.5 (0.5, 0.5)
	Pain	2625	0.0 (0.0, 0.0)	0.1 (0.1, 0.1)	0.2 (0.2, 0.2)	0.3 (0.3, 0.3)	0.4 (0.4, 0.4)	0.5 (0.5, 0.5)
	Other	3981	0.2 (0.2, 0.2)	0.4 (0.4, 0.4)	0.5 (0.5, 0.5)	0.6 (0.6, 0.6)	0.7 (0.7, 0.7)	0.7 (0.7, 0.7)

Please refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions. The third-party trademarks used herein are the trademarks of their respective owners.



depuysynthes.com

© DePuy Synthes 2022. All rights reserved.  
215957-221122 DSUS/EMEA

Johnson & Johnson Medical Limited, Baird House, 4 Lower Gilmore Bank, Edinburgh, EH3 9QP, United Kingdom. Incorporated and registered in Scotland under company number SC132162.

**DePuy Orthopaedics, Inc.**  
700 Orthopaedic Drive  
Warsaw, IN 46582  
USA  
Tel: +1 (800) 366 8143  
Fax: +1 (800) 669 2530

**DePuy International Ltd**  
St Anthony's Road  
Leeds LS11 8DT  
England  
Tel: +44 (0)113 270 0461

**DePuy Ireland UC**  
Loughbeg  
Ringaskiddy  
Co. Cork  
Ireland  
Tel: +353 21 4914 000  
Fax: +353 21 4914 199

# Two-year Survivorship and Clinical Outcomes of Total Knee Arthroplasty with a New Tibial Design from a Multi-Center Registry



Donald Pomeroy, MD<sup>1</sup>; Michael Swank, MD<sup>2</sup>; John Irving<sup>3</sup>, MD; Sean Croker, MS<sup>4</sup>; David Fawley, MA, MS<sup>4</sup>; Andrew Spitzer, MD<sup>5</sup>

1) The Arthroplasty Foundation, Louisville, KY, USA; 2) Beacon Orthopaedics & Sports Medicine, Cincinnati, OH, USA; 3) Connecticut Orthopaedics, Hamden, CT, USA; 4) DePuy Synthes, Warsaw, IN, USA; 5) Cedars-Sinai Orthopaedics, Los Angeles, CA, USA



## BACKGROUND

In 2011, the ATTUNE™ Knee System (DePuy Synthes, Warsaw, IN) was released and since that time has performed well according to numerous registry reports and peer-reviewed publications. A new tibial tray design (ATTUNE S+™ Technology) was released in 2017, which included a microblast finish to increase surface roughness, cement-implant interdigitation, and reduce fluid infiltration at the cement-implant interface. In addition, four cement pockets with 45° undercut pockets provide a “macrolock” between the implant and cement.

## OBJECTIVES

To assess survivorship of this knee system, including the new tibia, utilizing a multi-center, retrospective case review from a company sponsored registry.

## DESIGN AND METHODS

Clinical assessments were summarized at standardized registry visit windows, which were back-to-back and included all follow-up data. Kaplan-Meier (KM) survivorship was performed with revision of the tibial component and revision of any component as endpoints, with two separate censoring assumptions. First, unrevised subjects were censored at the last clinical follow-up [clinical assumption (CA)], and second at the date of database extract [registry assumption (RA)]. Survivorship was not calculated at timepoints where <40 knees were available for follow up. Tibial component survivorship was censored at the time of revision of other components.

## RESULTS

A total of 2626 knees were implanted between September 2017 and November 2021. Primary diagnosis was osteoarthritis in 98.9% of cases. Mean age was 67.6 years (range 36-94), 55% were female and BMI averaged 30.3 (range 15 to 54). There were 26 revisions; reasons for revision (N; %) are shown in Table 1. The tibial component was revised in 10 of these cases, for a diagnosis (N) of instability (3), loosening (2), infection (2), pain/stiffness (2), and implant fracture (1). KM estimates for revision of any component and revision of the tibial component (95% CI; N with further follow-up) are presented in Table 2. Plots of the KM survivorship of the TKA construct with 95% confidence interval (shaded) is provided in Figure 1, and for the tibial component in Figure 2. Mean American Knee Society (pre-2011) total scores (SD; N) are shown in Table 3.

## CONCLUSION

In an observational registry data setting it is believed that RA tends to overestimate survivorship estimates, whereas CA has the potential to underestimate survivorship; this report included both analysis methods to improve transparency. This knee system with the new tibia component is performing at least equivalently to other knee systems in registries. Tibial loosening is low risk with KM survivorship for the tibia ranging between 98.8% and 99.6% at 2 years postoperatively for both assumptions. Further study is planned to evaluate whether this early success persists with longer follow up.

Table 1: Revisions

Revision Reason	N	% of Revisions
Instability	16	61.5
Pain/Stiffness	4	15.4
Tibial Loosening	2	7.7
Infection	2	7.7
Patellar Fracture	1	3.8
Dislocation/Subluxation	1	3.8
TOTAL	26	

Table 2: Kaplan-Meier Survivorship Estimates

All Knees (N=2626)	1 Year KM Survivorship KM Estimate (95% CI) N with Later Follow-up	2 Year KM Survivorship KM Estimate (95% CI) N with Later Follow-up	3 Year KM Survivorship KM Estimate (95% CI) N with Later Follow-up
All Cause Revision – CA	98.4% (97.2%, 99.1%) N= 577	95.1% (92.0%, 97.0%) N= 150	N<40 knees
All Cause Revision – RA	99.4% (99.0%, 99.7%) N= 2041	98.9% (98.4%, 99.3%) N= 1294	98.6% (97.8%, 99.0%) N= 506
Tibial Revision – CA	99.2% (98.3%, 99.6%) N= 577	98.8% (97.1%, 99.5%) N= 150	N<40 Knees
Tibial Revision – RA	99.7% (99.4%, 99.9%) N= 2041	99.6% (99.3%, 99.8%) N= 1294	99.4% (98.9%, 99.7%) N= 506

Table 3: Knee Society Scores (KSS)

	Mean Pre-op KSS (SD; N)	Mean 1 Year KSS (SD; N)	Mean 2 Year KSS (SD; N)	Mean 3 Year KSS (SD; N)
All Knees	45.0	90.9	92.4	94.1
(N=2626)	(17.9; 1870)	(11.4; 645)	(9.6; 172)	(5.3; 50)

Figure 1: Any Component Kaplan-Meier Survivorship and 95% CI





Figure 2: Tibial Component Kaplan-Meier Survivorship and 95% CI



Please refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions.

© DePuy Synthes 2022. All rights reserved. 215957-221122 DSUS/EMEA

Information presented here reflect data through 13OCT2021